Gammagard S/D Alternatives Compared
| Gammagard S/D (immune globulin intravenous) | Nplate (romiplostim) | Promacta (eltrombopag) |
|
|---|
| Gammagard S/D (immune globulin intravenous) | Nplate (romiplostim) | Promacta (eltrombopag) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Primary Immunodeficiency Syndrome, Chronic Lymphocytic Leukemia, Immune Thrombocytopenia, Kawasaki Disease. Gammagard S/D may also be used for purposes not listed in this medication guide. View more |
Prescription only
Nplate may be used to increase platelet counts above 50 x 109/L in adults and children with ITP who have not had a good response to corticosteroids, immunoglobulins, or removal of their... View more |
Prescription only
Promacta is an oral tablet or suspension that is taken daily to boost platelet numbers in people with chronic ITP, severe aplastic anemia, or chronic hepatitis C. Nausea, diarrhea, infections, and... View more |
Related suggestions Immune Thrombocytopenia
|
|||||||||||||||||||||||
| More about Gammagard S/D (immune globulin intravenous) | More about Nplate (romiplostim) | More about Promacta (eltrombopag) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Gammagard S/D has an average rating of 7.0 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
Nplate has an average rating of 7.6 out of 10 from a total of 10 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 10% reported a negative effect. |
Promacta has an average rating of 7.3 out of 10 from a total of 18 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 20% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Gammagard S/D prices |
View all Nplate prices |
View all Promacta prices |
||||||||||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other immune globulin intravenous brands include: Alyglo, Asceniv, Bivigam, Carimune NF, Flebogamma, Gammaplex, Octagam, Panzyga, Privigen, Yimmugo View more |
N/A |
Other eltrombopag brands include: Alvaiz, Promacta Kit | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
576 hours |
816 hours |
35 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 104 drugs are known to interact with Gammagard S/D:
|
A total of 9 drugs are known to interact with Nplate:
|
A total of 183 drugs are known to interact with Promacta:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
August 22, 2008 |
November 20, 2008 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.